A Randomized Phase II Trial for High-Risk Multiple Myeloma That is Refractory or in First Relapse With Daratumumab, Teclistamab (DT) Versus Daratumumab, Pomalidomide, Dexamethasone (DPd) or Daratumumab, Carfilzomib, Dexamethasone (DKd)
Latest Information Update: 17 Jun 2025
At a glance
- Drugs Daratumumab/hyaluronidase (Primary) ; Teclistamab (Primary) ; Carfilzomib; Dexamethasone; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
Most Recent Events
- 11 Jun 2025 Planned initiation date changed from 18 Jul 2025 to 31 Oct 2025.
- 07 May 2025 New trial record